Macrolide and occult infection in asthma

Current Opinion in Pulmonary Medicine

Volumn 10, Issue 1, 2004, Pages 7-14

  Cazzola, Mario ^a,d   Matera, Maria Gabriella ^b   Blasi, Francesco ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d NONE   (Italy)

Author keywords

Asthma; Atypical pathogens; Macrolide; Occult infection

Indexed keywords

CYTOKINE; INTERLEUKIN 8; MACROLIDE; MESSENGER RNA;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ASTHMA; BACTERIAL INFECTION; BRONCHODILATATION; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; DRUG EFFICACY; GENETIC TRANSCRIPTION; HUMAN; MYCOPLASMA PNEUMONIAE; REVIEW;

EID: 0347595294     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200401000-00003     Document Type: Review

References (71)

1. National Institutes of Health: Guidelines for the diagnosis and management of asthma-update on selected topics, 2002. National Asthma Education and Prevention Program. Bethesda (MD). J Allergy Clin Immunol 2002, 110:S141-S218.
2. Wahlstrom R, Hummers-Pradier E, Lundborg CS, et al.: Variations in asthma treatment in five European countries-judgement analysis of case simulations. Fam Pract 2002, 19:452-460.
3. Glauber JH, Fuhlbrigge AL, Finkelstein JA, et al.: Relationship between asthma medication and antibiotic use. Chest 2001, 120:1485-1492.
4. Oehling A: Bacterial immunotherapy in bronchial asthma. J Investig Allergol Clin Immunol 1997, 7:14-19.
5. Johnston SL, Pattemore PK, Sanderson G, et al.: Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995, 310:1225-1229.
6. Freymuth F, Vabret A, Brouard J, et al.: Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol 1999, 13:131-139.
7. Wark PA, Johnston SL, Simpson JL, et al.: Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma. Eur Respir J 2002, 20:834-840.
8. Lieberman D, Lieberman D, Printz S, et al.: Atypical pathogen infection in adults with acute exacerbation of bronchial asthma. Am J Respir Crit Care Med 2003, 167:406-410. Apparently, only infection with M. pneumoniae is associated with hospitalization for acute exacerbation of bronchial asthma.
9. Lemanske RF Jr: Is asthma an infectious disease? Chest 2003;123(suppl 3): 385S-390S.
10. von Hertzen LC: Role of persistent infection in the control and severity of asthma: focus on Chlamydia pneumoniae. Eur Respir J 2002, 19:546-556.
11. Kraft M, Cassell GH, Henson JE, et al.: Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med 2001, 164:513-514.
12. Ferrari M, Poli A, Olivieri M, et al.: Respiratory symptoms, asthma, atopy and Chlamydia pneumoniae IgG antibodies in a general population sample of young adults. Infection 2002, 30:203-207.
13. Martin RJ, Kraft M, Chu HW, et al.: A link between chronic asthma and chronic infection. J Allergy Clin Immunol 2001, 107:595-601.
14. Foschino Barbaro MP, Resta O, Aliani M, et al.: Seroprevalence of chronic Chlamydia pneumoniae infection in patients affected by chronic stable asthma. Clin Microbiol Infect 2002, 8:358-362.
15. Esposito S, Blasi F, Arosio C, et al.: Importance of acute Mycoplasma pneumoniae and Chlamydia pneumoniae infections in children with wheezing. Eur Respir J 2000, 16:1142-1146.
16. Thumerelle C, Deschildre A, Bouquillon C, et al.: Role of viruses and atypical bacteria in exacerbations of asthma in hospitalized children: a prospective study in the Nord-Pas de Calais region (France). Pediatr Pulmonol 2003, 35:75-82.
17. Casadevall A, Pirofski L: Host-pathogen interactions: the basic concepts of microbial commensalism, colonization, infection, and disease. Infect Immun 2000, 68:6511-6518.
18. Blasi F, Cosentini R, Tarsia P, et al.: Atypical pathogens and asthma: can they influence the natural history of the disease? Monaldi Arch Chest Dis 2001, 56:276-280.
19. Huittinen T, Hahn D, Antilla T, et al.: Host immune response to Chlamydia pneumoniae heat shock protein 60 is associated with asthma. Eur Respir J 2001, 17:1078-1082.
20. Bavoil P, Stephens RS, Falkow S: A soluble 60 kilodalton antigen of Chlamydia spp. is a homologue of Escherichia coli GroEL. Mol Microbiol 1990, 4:461-469.
21. Kol A, Bourcier T, Lichtman AH, et al.: Chlamydia and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest 1999, 103:571-577.
22. Bureau F, Bonizzi G, Kirschvink N, et al.: Correlation between nuclear factor-kB activity in bronchial brushing samples and lung dysfunction in an animal model of asthma. Am J Respir Crit Care Med 2000, 161:1314-1321.
23. Kol A, Sukhova GK, Lichtman AH, et al.: Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor α and matrix metalloproteinase expression. Circulation 1998, 98:300-307.
24. Libby P, Sukhova G, Lee RT, et al.: Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995, 25(suppl 2):S9-S12.
25. Gencay M, Roth M: Chlamydia pneumoniae infections in asthma: clinical implications. Am J Respir Med 2003, 2:31-38.
26. Betsou F, Sueur JM, Orfila J: Anti-Chlamydia pneumoniae heat shock protein 10 antibodies in asthmatic adults. FEMS Immunol Med Microbiol 2003, 35:107-111.
27. Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H: The role of IFN-γ in the outcome of chlamydial infection. Curr Opin Immunol 2002, 14:444-451.
28. Martin RJ, Chu HW, Honour JM, et al.: Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model. Am J Respir Cell Mol Biol 2001, 24:577-582.
29. Chu HW, Honour JM, Rawlinson CA, et al.: Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect Immun 2003, 71:1520-1526.
30. Hoek KL, Cassell GH, Duffy LB, et al.: Mycoplasma pneumoniae-induced activation and cytokine production in rodent mast cells. J Allergy Clin Immunol 2002, 109:470-476.
31. 1, in airway epithelial cells by Mycoplasma pneumoniae. Am J Respir Cell Mol Biol 2003, Apr:24. [Epub ahead of print]
32. Chmura K, Lutz RD, Chiba H, et al.: Mycoplasma pneumoniae antigens stimulate interleukin-8. Chest 2003, 123(suppl 3):425S.
33. Chiba H, Pattanajitvilai S, Mitsuzawa H, et al.: Pulmonary surfactant proteins A and D recognize lipid ligands on Mycoplasma pneumoniae and markedly augment the innate immune response to the organism. Chest 2003, 123(suppl 3):426S.
34. Kutlin A, Roblin PM, Hammerschlag MR: Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model. J Antimicrob Chemother 2002, 49:763-767.
35. Kutlin A, Roblin PM, Hammerschlag MR: Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother 2002, 46:409-412. Data of this study suggest that the dosage and duration of antibiotic therapy currently being used may not be sufficient to eradicate a putative chronic C. pneumoniae infection.
36. Black PN, Blasi F, Jenkins CR, et al.: Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001, 164:536-541.
37. Johnston SL: Is Chlamydia pneumoniae important in asthma? The first controlled trial of therapy leaves the question unanswered. Am J Respir Crit Care Med 2001, 164:513-514.
38. Kraft M, Cassell GH, Pak J, et al.: Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. Chest 2002, 121:1782-1788. This study supports the hypothesis that clarithromycin therapy improves lung function, but only in those subjects with positive polymerase chain reaction findings for M. pneumoniae or C. pneumoniae.
39. Cazzola M, Salzillo A, Diamare F: Potential role of macrolides in the treatment of asthma. Monaldi Arch Chest Dis 2000, 55:231-236.
40. Amayasu H, Yoshida S, Ebana S, et al.: Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 2000, 84:594-598.
41. Ekici A, Ekici M, Erdemoglu AK: Effect of azithromycin on the severity of bronchial hyperresponsiveness in patients with mild asthma. J Asthma 2002, 39:181-185.
42. Culic O, Erakovic V, Parnham MJ: Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001, 429:209-229.
43. Andrade WP, Renard RL, Nelson HS: The effect of troleandomycin and methylprednisolone alone and in combination on bronchial sensitivity to methacholine. Ann Allergy 1983, 51:515-617.
44. Itkin IH, Menzel ML: The use of macrolide antibiotic substances in the treatment of asthma. Allergy 1970, 45:146-162.
45. LaForce CF, Szefler SJ, Miller MF, et al.: Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983, 72:34-39.
46. von Rosensteil NA, Adam D: Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995, 13:105-122.
47. Shimizu T, Kalo M, Mochizuki H, et al.: Roxithromycin attenuates acid-induced cough and water-induced bronchoconstriction in children with asthma. J Asthma 1997, 34:211-217.
48. Konno S, Adachi M, Asano K, et al.: Anti-allergic activity of roxithromycin: inhibition of interleukin-5 production from mouse T lymphocytes. Life Sci 1993, 52:PL25-PL30.
49. Konno S, Asano K, Kurokawa M, et al.: Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. Int Arch Allergy Immunol 1994, 105:308-316.
50. Adachi T, Motojima S, Hirata A, et al.: Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J Allergy Clin Immunol 1996, 98:S207-S215.
51. Miyatake H, Suzuki K, Taki F, et al.: Effect of erythromycin on bronchial hyperresponsiveness in patients with bronchial asthma. Arzneimittelforschung 1991, 41:815-820.
52. Tamaoki J, Tagaya E, Sakai A, et al.: Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. J Allergy Clin Immunol 1995, 95:853-859.
53. Garey KW, Alwani A, Danziger LH, et al.: Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003, 123:261-265. Long-term, low-dose administration of 14- and 15-membered ring macrolide antibiotics may represent an important adjunct in the treatment of chronic inflammatory sinopulmonary diseases in humans. In fact, it is associated with down-regulation of nonspecific host inflammatory response to injury and promotion of tissue repair.
54. Hoyt JC, Robbins RA: Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol Lett 2001, 205:1-7.
55. Zalewska-Kaszubska J, Gorska D: Anti-inflammatory capabilities of macrolides. Pharmacol Res 2001, 44:451-454.
56. Jaffe A, Bush A: Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001, 31:464-473.
57. Labro MT, Abdelghaffar H: Immunomodulation by macrolide antibiotics. J Chemother 2001, 13:3-8.
58. Kohyama T, Takizawa H, Kawasaki S, et al.: Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 1999, 43:907-911.
59. Sato E, Nelson DK, Koyama S, et al.: Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro. Antimicrob Agents Chemother 2001, 45:401-406.
60. Roche WR, Beasley R, Williams JH, et al.: Subepithelial fibrosis in the bronchi of asthmatics. Lancet 1989, 1:520-524.
61. Takamizawa A, Koyama S, Sato E, et al.: Bleomycin stimulates lung fibroblasts to release neutrophil and monocyte chemotactic activity. J Immunol 1999, 162:6200-6208.
62. Teran LM, Mochizuki M, Bartels J, et al.: Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts. Am J Respir Cell Mol Biol 1999, 20:777-786.
63. Yamanaka Y, Tamari M, Nakahata T, et al.: Gene expression profiles of human small airway epithelial cells treated with low doses of 14- and 16-membered macrolides. Biochem Biophys Res Commun 2001, 287:198-203.
64. Deng Z, Centola M, Chen X, et al.: Identification of two Kruppel-related zinc finger genes (ZNF200 and ZNF210) from human chromosome 16p13.3. Genomics 1998, 53:97-103.
65. Barnes PJ, Adcock IM: Transcription factors and asthma. Eur Respir J 1998, 12:221-234.
66. Ichiyama T, Nishikawa M, Yoshitomi T, et al.: Clarithromycin inhibits NF-κB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. Antimicrob Agents Chemother 2001, 45:44-47.
67. Abe S, Nakamura H, Inoue S, et al.: Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am J Respir Cell Mol Biol 2000, 22:51-60.
68. Noma T, Aoki K, Hayashi M, et al.: Effect of roxithromycin on T lymphocyte proliferation and cytokine production elicited by mite antigen. Int Immunopharmacol 2001, 1:201-210.
69. Noma T, Ogawa N: Roxithromycin enhances lymphocyte apoptosis in Dermatophagoides-sensitive childhood asthma. J Allergy Clin Immunol 2003, 111:646-647. In a short letter, the authors suggest that the impaired apoptotic response of lymphocytes to D. farinae stimulation in patients with mite-sensitive asthma can be reversed by treatment with roxithromycin. Induction of Fas/Fas ligand (that mediates apoptosis) and reduced Bcl-2 (an antiapoptotic protein) expression might contribute to this increased apoptosis.
70. Noma T, Sugawara Y, Aoki K, et al.: Induction of peripheral mononuclear cell apoptosis in asthmatic patients in remission. J Asthma 2002, 39:591-601.
71. Richeldi L, Ferrara G, Fabbri LM, et al.: Macrolides for chronic asthma. Cochrane Database Syst Rev 2002, 1:D002997. This Cochrane analysis shows that there is insufficient evidence to support or to refute the use of macrolides in patients with chronic asthma.